Search research articles
Contact Us
Filters
Showing results (61-70 of 98) with videos related to
Page
of 10
Sort By:
JACC. Heart Failure
|
October 25, 2024
Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial
Mikhail N Kosiborod, Elke Platz, Sean Wharton, et al.
Clinical Obesity
|
November 25, 2024
Healthcare utilization associated with obesity management in Ontario, Canada
Sean Wharton, Adel Belloum, Maria Luckevich, et al.
Diabetes, Obesity & Metabolism
|
November 4, 2025
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1)
Carel W le Roux, Sean Wharton, Biykem Bozkurt, et al.
Diabetes, Obesity & Metabolism
|
September 13, 2021
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
Sean Wharton, Salvatore Calanna, Melanie Davies, et al.
Diabetes, Obesity & Metabolism
|
November 11, 2025
Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes
Sean Wharton, Carel W le Roux, Biykem Bozkurt, et al.
The New England Journal of Medicine
|
June 3, 2022
Tirzepatide Once Weekly for the Treatment of Obesity
Ania M Jastreboff, Louis J Aronne, Nadia N Ahmad, et al.
Nature Medicine
|
October 10, 2022
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
W Timothy Garvey, Rachel L Batterham, Meena Bhatta, et al.
JACC. Heart Failure
|
December 2, 2025
Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial
Elke Platz, Lee M Kaplan, Carel W le Roux, et al.
The New England Journal of Medicine
|
June 23, 2023
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Sean Wharton, Thomas Blevins, Lisa Connery, et al.
Lancet (London, England)
|
August 21, 2018
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Patrick M O'Neil, Andreas L Birkenfeld, Barbara McGowan, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 98) with videos related to
Sort By:
Page
of 10
JACC. Heart Failure
|
October 25, 2024
Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial
Mikhail N Kosiborod, Elke Platz, Sean Wharton, et al.
Clinical Obesity
|
November 25, 2024
Healthcare utilization associated with obesity management in Ontario, Canada
Sean Wharton, Adel Belloum, Maria Luckevich, et al.
Diabetes, Obesity & Metabolism
|
November 4, 2025
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1)
Carel W le Roux, Sean Wharton, Biykem Bozkurt, et al.
Diabetes, Obesity & Metabolism
|
September 13, 2021
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
Sean Wharton, Salvatore Calanna, Melanie Davies, et al.
Diabetes, Obesity & Metabolism
|
November 11, 2025
Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes
Sean Wharton, Carel W le Roux, Biykem Bozkurt, et al.
The New England Journal of Medicine
|
June 3, 2022
Tirzepatide Once Weekly for the Treatment of Obesity
Ania M Jastreboff, Louis J Aronne, Nadia N Ahmad, et al.
Nature Medicine
|
October 10, 2022
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
W Timothy Garvey, Rachel L Batterham, Meena Bhatta, et al.
JACC. Heart Failure
|
December 2, 2025
Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial
Elke Platz, Lee M Kaplan, Carel W le Roux, et al.
The New England Journal of Medicine
|
June 23, 2023
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Sean Wharton, Thomas Blevins, Lisa Connery, et al.
Lancet (London, England)
|
August 21, 2018
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Patrick M O'Neil, Andreas L Birkenfeld, Barbara McGowan, et al.
Page
of 10